Lakefront Biotherapeutics NV (LKFT)
| Market Cap | 1.93B |
| Revenue (ttm) | 1.20B |
| Net Income (ttm) | 563.56M |
| Shares Out | 65.90M |
| EPS (ttm) | 8.55 |
| PE Ratio | 3.43 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 130,070 |
| Open | 28.77 |
| Previous Close | 28.84 |
| Day's Range | 28.72 - 29.54 |
| 52-Week Range | 26.42 - 37.78 |
| Beta | 0.13 |
| Analysts | Sell |
| Price Target | 22.81 (-22.68%) |
| Earnings Date | Aug 10, 2026 |
About LKFT
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relaps... [Read more]
Financial Performance
In 2025, LKFT's revenue was 1.11 billion, an increase of 303.50% compared to the previous year's 275.65 million. Earnings were 320.88 million, an increase of 333.15%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for LKFT stock is "Sell." The 12-month stock price target is $22.81, which is a decrease of -22.68% from the latest price.
News
Acquisition of Own Shares
Mechelen, Belgium; 23 June 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lak...
Lakefront Biotherapeutics announces EUR 50M share repurchase program
Lakefront Biotherapeutics (LKFT) announced the launch of a share repurchase program, under which the company may repurchase ordinary shares for an aggregate amount of up to EUR 50M. Repurchases under…
Lakefront Announces Initiation of €50 Million Stock Repurchase Program
Mechelen, Belgium ; June 9, 2026, 22:01 CET; regulated information – Lakefront Bio therapeutics NV (Euronext & NASDAQ: LKFT) today announced the launch of a share repurchase program (the “Program”), u...
Lakefront Biotherapeutics appoints Eric Hedrick chief medical officer
Lakefront Biotherapeutics (LKFT) announced that Eric Hedrick has been appointed chief medical officer. Hedrick report to Henry Gosebruch, CEO and join the company’s management committee. Prior to join...
Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer
Mechelen, Belgium ; June 8, 2026, 22:01 CET; Lakefront Bio therapeutics NV (Euronext & NASDAQ: LKFT) today announced that Eric Hedrick, MD has been appointed Chief Medical Officer. This expanded leade...